HEALTH TECHNOLOGY

Pyramid Healthcare Optimizes the Delivery of Mental Health Services over the Cloud with iland IaaS

iland Cloud | October 05, 2021

iland, a leading VMware-based cloud provider for application hosting, data protection and disaster recovery services delivered on the iland Secure Cloud Platform, today announced Pyramid Healthcare is using the iland Secure Cloud to assist with the provision of critical management information, allowing it to provide high quality treatment for adults and teens suffering from addiction and mental health disorders.

 

Pyramid Healthcare provides treatment and rehabilitation services to more than 11,000 patients in seven states, including Connecticut, Virginia, Pennsylvania, New Jersey, Maryland, North Carolina and Georgia with the support of more than 2,400 employees. Three years ago, the company began looking for a cloud solution to team with its electronic medical record data (EMR) to provide business intelligence (BI).

 

Pyramid Healthcare CIO Lawrence Bilker said the company was running out of room for traditional on-premises data center resources and needed a secure cloud platform that was flexible, affordable and scalable to meet the performance and capacity demands of its BI workloads. After looking at several options, Bilker and his team selected iland’s Hosted Private Cloud, which combines the proven technology of Secure Public Cloud with dedicated resources to deliver unprecedented performance and security. Since then, the Pyramid Healthcare has been running in the cloud without interruption. 

 

"Since we set up the iland Secure Cloud, the performance has been solid and consistent," Bilker said. "We've been up and running since then 24 hours a day, seven days a week, 365 days a year, which helps us make faster decisions and run our business more efficiently. With iland, we can react to changing business conditions faster and add performance and capacity, which we can monitor with ease over iland's cloud console."

 

iland Secure Cloud was designed to eliminate customer compromises by addressing the most common challenges associated with cloud adoption and providing everything customers need to satisfy even the most complex application requirements. For example, the Secure Cloud Console, iland’s award-winning, unified management platform, allows Pyramid Healthcare to have complete control and deep visibility into its cloud infrastructure resources.

 

“iland is proud to help introduce organizations like Pyramid Healthcare to the cloud. iland innovations like the Secure Cloud and Secure Cloud Console help remove the work and risks of moving critical applications and workloads to the cloud. It also makes it easier to expand resources and technologies like DRaaS and BaaS, all monitored and managed over a single pane of glass in a compliant environment that meets and exceeds regulatory requirements such as HIPAA.” 

iland President and Co-founder Brian Ussher

 

Based on his experience with the iland Secure Cloud, Bilker said Pyramid Healthcare is evaluating iland’s DRaaS to help protect the company’s data and operations during times of disaster and cybercrime with the visibility and manageability offered over the Secure Cloud Console.

 

“iland gives us the flexibility we need to change and add to our infrastructure to address our immediate needs or what lies ahead,” he said. “If you’re looking for a partner that can provide an IaaS platform that has high availability at a reasonable cost and the flexibility to adapt to changing business needs, iland is a phenomenal choice.”

 

About iland

iland is a global cloud service provider of secure and compliant hosting for infrastructure (IaaS), disaster recovery (DRaaS) and backup as a service (BaaS). They are recognised by industry analysts as a leader in disaster recovery. The award-winning iland Secure Cloud Console natively combines deep layered security, predictive analytics and compliance to deliver unmatched visibility and ease of management for all of iland’s cloud services. Headquartered in Houston, Texas and London, UK, and Sydney, Australia, iland delivers cloud services from its cloud regions throughout North America, Europe, Australia, and Asia. 

Spotlight

The ability to access data from medical devices is only the first step to improved patient safety. To fully realize the value of the data, you need to be able to define what “safe” looks like and be alerted to unsafe conditions. With the NaviCare® Patient Safety Application, we can help you do just that… all without pressing a button. The information contained in these videos is provided for educational purposes only and is not intended nor implied to be a substitute for professional medical advice. You assume full responsibility for how you choose to use this information. Please speak with your healthcare provider about any questions you may have regarding a medical condition.


Other News
MEDICAL DEVICES

CeloNova Announces New Strategic Direction Focused on Creating Partnership

CeloNova BioSciences, Inc. | April 08, 2022

CeloNova BioSciences, Inc. developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimize implant interaction within the body. The company's nanocoated innovation is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date. "We are pleased to offer leading medical device manufacturers access to the unique clinical advantages of our Polyzene-F nanocoated technology that has clinically demonstrated low thrombosis, restenosis and inflammation with rapid healing effects," stated Carl St. Bernard, President and Chief Executive Officer of CeloNova. "This technology offers a significant benefit to companies seeking to improve the clinical performance of their implant technologies." "I fully support CeloNova's new strategic direction which allows medical device manufacturers to benefit from long-term biocompatibility and thromboresistance of Polyzene-F. When my students and I set out to study the hemocompatibility of this inorganic polymer in our lab in Heidelberg Germany, we soon realized its potential to significantly limit a wide range of implant complications and being broadly applied in the human body and in biomedical devices." Professor Dr. Michael Grunze, Former Chair and Professor (emeritus) at the Institute of Applied Physical Chemistry of the Ruprecht-Karls-University in Heidelberg and co-inventor of Polyzene-F CeloNova is based on a rich history of medical innovation with two PzF coated medical implants successfully commercialized in the U.S. and the EU. The company's PzF coated embolic microspheres product line was sold to Boston Scientific in 2015 and the COBRA PzF NanoCoated Coronary Stent, was developed to safely and effectively treat patients who may benefit from 1-month of dual antiplatelet therapy. CeloNova's new business direction builds upon the successful application of PzF in interventional oncology and cardiology and expands its opportunities through the development of new surface coating technologies to address important unmet clinical needs. "In my pre-clinical research at CVPath since 2012, CeloNova's proprietary Polyzene-F coating has consistently demonstrated a unique advantage of allowing an implant to heal quickly and in a functional way, without the need for antiproliferative drug elution," stated Aloke Finn, MD, Medical Director and Chief Scientific Officer at CVPath and Associate Professor of Medicine at the University of Maryland. "I believe Polyzene-F will continue to play an important role in delivering safety and efficacy in clinical practice." Polyzene-F is a proprietary, ultra-pure and highly elastic surface coating possessing unique mechanical properties that allow an implant to be coated at a nanoscale level. The coating acts as a biocompatible barrier between the implant, intimal surface and circulating elements in the blood and has demonstrated thromboresistant and anti-inflammatory properties with significantly faster, higher quality healing compared to market-leading technologies.1* About CeloNova BioSciences, Inc. CeloNova BioSciences, Inc. is a global medical device company that develops, manufactures and markets novel surfaced coated technologies, including its proprietary Polyzene™-F nanocoating. The next generation nanocoating is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date.

Read More

FUTURE OF HEALTHCARE

UMC Health System Partners with Omnicell for Advanced Services Solutions to Streamline Medication Management & Enhance Clinical Outcomes

Omnicell | February 15, 2022

Omnicell, Inc., a leading provider of medication management and adherence tools for health systems and pharmacies, today announced that UMC Health System (“UMC”) in Lubbock, Texas, has selected Omnicell’s comprehensive portfolio of Advanced Services solutions to support key pharmacy initiatives, including acute care, outpatient, retail, and 340B program strategies. UMC has signed a 10-year sole source agreement for Omnicell’s cloud-based portfolio of solutions, including central pharmacy automation and point of care dispensing systems. The partnership is also expected to support UMC’s goals of expanding community pharmacy services through opportunities with Omnicell’s 340B services and EnlivenHealth’s patient engagement solutions, helping UMC to drive operational efficiency across its continuum of care. More importantly, these solutions will empower pharmacy staff and clinicians to focus on higher value tasks that support patient safety. As a public hospital with a 40-year tenure supporting the Lubbock community, UMC has experienced an increase in demand for its services. According to U.S. Census data, Texas has one of the highest uninsured population rates – at 18.4 percent in 2019, nearly double the national average. Programs like the federal 340B Drug Pricing Program and technology-enabled patient engagement solutions are intended to help improve health outcomes for these underserved communities. “At UMC, our top priority is patient safety and ensuring healthy outcomes for our community. Partnering with Omnicell, we are building an advanced pharmacy technology strategy that aligns with our vision to streamline and advance the pharmacy and nursing practice across our system. Most importantly, we are laying a technology foundation that will enable the best patient care.” John Lowe, vice president of Support Services at UMC Health System UMC has embraced the industry-defined vision of the Autonomous Pharmacy, a roadmap designed to develop a zero-error, fully automated medication management infrastructure. Through automation, intelligence, and expert services, the Autonomous Pharmacy is expected to drive performance and outcomes, and empower clinicians to shift their focus from manual administrative functions to patient support needs. “As medication management becomes more complex, we believe health systems need end-to-end, cloud-based solutions that will allow them to work smarter, while supporting safe, efficient pharmacy care,” said Scott Seidelmann, executive vice president and chief commercial officer at Omnicell. “We’re confident that Omnicell’s partnership with UMC will provide comprehensive solutions that bridge acute and ambulatory care to help enhance performance and that are designed to deliver the highest levels of patient safety across the health system.” About UMC UMC Health System is a national award-winning health system comprised of over 4,600 team members and more than 30 care locations. We are proud to partner with Texas Tech University Health Sciences Center to provide the best care to West Texas and Eastern New Mexico. Whether you are managing a chronic condition, dealing with an unexpected illness, or simply working to stay healthy, we are passionate about getting you well and helping you stay that way. At UMC, Our Passion is You. About Omnicell Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Healthcare facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.

Read More

HEALTH TECHNOLOGY

InfuSystem Announces Master Service Agreement with Leading Global Healthcare Technology and Diagnostic Company

InfuSystem Holdings, Inc. | April 29, 2022

InfuSystem Holdings, Inc. a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it has entered into a three-year master service agreement with a leading global healthcare technology and diagnostic company, effective April 25, 2022. As part of the master service agreement, InfuSystem will be providing its biomedical services, which include annual preventative maintenance and repair solutions, to a majority of the fleet of infusion pumps at hospitals and other medical facilities under contract with this tier one global healthcare company. Service will be conducted on-site at the acute care facility or off-site at one of InfuSystem’s seven service centers. This global healthcare technology and diagnostic company’s preferred customers’ infusion pump fleet consists of more than 300,000 pumps located in 1,200 medical facilities, including 800 hospital systems in the U.S. and Canada. This preferred national service agreement is estimated to generate approximately $10 to $12 million, after an initial ramp-up period, in annual revenue under InfuSystem’s DME service platform. “I am extremely pleased the tier one global healthcare company has entrusted InfuSystem to be their preferred national service provider. We will deliver our 'white glove' biomedical services for their infusion pump fleet throughout North America. This master service agreement could potentially lead to additional opportunities to serve this customer to provide other products and services we offer under our DME Services segment. The wide-ranging expertise and capabilities of our DME platform, along with our proven track record of industry-leading service, and our national network of service centers, were important factors in their decision to partner with InfuSystem.” Richard DiIorio, Chief Executive Officer of InfuSystem “This acute care service opportunity is the direct result of effectively integrating our biomedical services acquisitions and creating a highly effective operating unit to service tier one clients in order to drive growth and significantly expand market share. Our certified biomedical service teams will be deployed throughout North America to commence onboarding of the global healthcare company’s infusion fleet, and to conduct service and repairs on-site or at one of our national service centers. I believe this preferred national service agreement lays the foundation for long-term growth of our DME business and even greater expansion into the acute care space.” “This master service agreement represents a significant milestone for the Company. It is a testament to our team’s hard work and dedication in providing industry-leading service and repair solutions. We look forward to a long and successful relationship for years to come,” concluded Mr. DiIorio. About InfuSystem Holdings, Inc. InfuSystem Holdings, Inc. is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services (“ITS”), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, Wound Therapy and Lymphedema businesses. The second platform, Durable Medical Equipment Services (“DME Services”), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payer clients. The DME Services segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.

Read More

FUTURE OF HEALTHCARE

Omega Healthcare completes acquisition of ApexonHealth and Vasta Global

Omega Healthcare | April 18, 2022

Omega Healthcare, a leading technology-enabled healthcare management solutions provider,announced its acquisition of ApexonHealth, an AI and automation-based revenue cycle management and payor solutions provider, and Vasta Global, a provider of real-world data abstraction and analytics for the oncology market. ApexonHealth leverages its digital solutions to deliver comprehensive technology-enabled services for both providers and payors from revenue cycle management and coding to claims management and advanced analytics. ApexonHealth's cognitive and automation capabilities have significantly reduced manual effort and increased accuracy in claims adjudication strengthening its payor services. ApexonHealth's expertise in the healthcare payor sector will augment Omega's existing payor-focused offerings. Vasta Global provides clinical data management with a focus on the oncology market and provides real-world evidence data curation and analytics, clinical trial support, and cancer registry services for cancer centers. Vasta Global's customers span the entire healthcare ecosystem including providers, pharmaceutical and biotechnology companies, and contract research organizations that provide clinical trial management services. The two acquisitions will complement Omega Healthcare's existing strengths in revenue cycle management and clinical data management for various medical registries including cancer, stroke, and trauma. These acquisitions are part of the strategy to accelerate Omega's journey in scaling its portfolio of AI- and data-analytics- based solutions to help healthcare clients optimize revenue while reducing cost through leveraging of big data and automation technology. With the recently completed acquisition of Reventics, Omega Healthcare will deliver an end-to-end revenue cycle management suite of solutions to healthcare providers, from analytics-driven clinical documentation improvement to platforms for payment data management. The Company will also expand its oncology-focused offering to now include big data capture and reporting to help healthcare providers and pharmaceutical companies leverage complex, longitudinal data to improve cancer treatment. "We are pleased to welcome ApexonHealth and Vasta Global to the Omega family. We've been very impressed by the vision and execution by the two management teams. Bringing together the Omega, ApexonHealth, and Vasta offerings together will unlock significant value to our clients." Anurag Mehta, CEO of Omega Healthcare "I am thrilled about this opportunity to join the Omega platform. Our mission to provide sustainable and scalable solutions to our clients is one that is shared by the Omega Healthcare team. With their broad capabilities, we are excited to offer our clients access to data curation, registry management, and machine learning solutions. Through this alliance, we reinforce our commitment to scientific discovery for patients through accelerated clinical research and real-world data," said Kinjal Vora, CEO of Vasta Global. "We are pleased to welcome ApexonHealth and Vasta Global to the Omega family," commented Harsh Nanda, Managing Director and Head of Technology Private Equity within Goldman Sachs Asset Management. "With the acquisitions of Reventics, ApexonHealth, and Vasta Global, Omega now services more than 350 customers spanning the entire healthcare continuum with the support of robust technology-led solutions and insights. Together, we can help our clients enhance the patient experience while improving operational efficiency and strengthen our position as the partner of choice for the healthcare ecosystem." About Omega Healthcare Founded in 2003, Omega Healthcare helps payors, providers, and pharmaceutical companies eliminate administrative burdens, accelerate cash flow, and reduce health management costs while enhancing patient care. The company streamlines medical billing, coding, and collections processes and provides virtual nursing services, including triage, care continuation, clinical documentation improvement, and re-admittance avoidance. Combining the largest medical coding staff in the world with proprietary technology, analytics, and automation capabilities, Omega Healthcare provides the most comprehensive outsourced solutions in the industry and is ranked among the top revenue cycle management business process services by industry analysts. About ApexonHealth Founded in 1996, ApexonHealth provides healthcare-focused digital solutions that combine the best of cutting-edge technology around machine learning, workflow automation, and business process automation to deliver comprehensive services for both providers and payors from revenue cycle management and coding to claims management and advanced analytics. Having helped 80+ healthcare organizations in 14+ years transform their RCM systems, ApexonHealth is actively involved and supports various healthcare bodies like the American Health Information Management Association (AHIMA), American Academy of Professional Coders (AAPC), and more. About Vasta Global Vasta Global offers solutions for data management, clinical research, bioinformatics consulting, and business process outsourcing. With over a decade of experience in cancer research and medical information management, Vasta Global is committed to providing sustainable and scalable solutions for clinical research and bioinformatics needs. The company's information technology and data management solutions streamline and integrate research and patient care workflows while collecting quality data, achieving research goals, and shaping the clinical practice guidelines of tomorrow. About Goldman Sachs Asset Management Bringing together traditional and alternative investments, Goldman Sachs Asset Management provides clients around the world with a dedicated partnership and focus on long-term performance. As the primary investing area within Goldman Sachs, we deliver investment and advisory services for the world's leading institutions, financial advisors and individuals, drawing from our deeply connected global network and tailored expert insights, across every region and market—overseeing more than $2 trillion in assets under supervision worldwide as of December 31, 2021. Driven by a passion for our clients' performance, we seek to build long-term relationships based on conviction, sustainable outcomes, and shared success over time. About Everstone Capital Partners Everstone is a premier investment group focused on cross-border North America – Asia investments and domestic investments in India and Southeast Asia, with assets of ~US$7 billion across private equity, real estate, credit, climate change and green infrastructure, and venture capital. Everstone has a significant resource base across its seven offices in Singapore, India, New York, Mauritius and UAE, comprising best-of-breed investing, operations and strategic resources with extensive skills and experience.

Read More

Spotlight

The ability to access data from medical devices is only the first step to improved patient safety. To fully realize the value of the data, you need to be able to define what “safe” looks like and be alerted to unsafe conditions. With the NaviCare® Patient Safety Application, we can help you do just that… all without pressing a button. The information contained in these videos is provided for educational purposes only and is not intended nor implied to be a substitute for professional medical advice. You assume full responsibility for how you choose to use this information. Please speak with your healthcare provider about any questions you may have regarding a medical condition.

Resources